Stockreport

Spin-Off Research Slashes Mural Oncology Valuation [Forbes]

Mural Oncology plc - Ordinary Shares  (MURA) 
PDF immunotherapies, provided an update on the Phase 3 ARTISTRY-7 trial of Nemvaleukin in combination with KEYTRUDA® (pembrolizumab) in patients with Platinum-Resistant Ovar [Read more]